Biopharma's biggest sellers – the oldies that just keep giving
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Private European companies enjoy their own treasure bath
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
Oncology's haves and have-nots
A handful of tumour types have disproportionately benefited from the sector’s huge push into oncology. Is the investment case weakening in certain areas?
Novel drug approvals head for a down year
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
De novo device clearances fall out of fashion
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Gilead-Galapagos deal rescues a slow licensing year
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.